Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.
Segeren CM, Sonneveld P, van der Holt B, Baars JW, Biesma DH, Cornellissen JJ, Croockewit AJ, Dekker AW, Fibbe WE, Löwenberg B, van Marwijk Kooy M, van Oers MH, Richel DJ, Schouten HC, Vellenga E, Verhoef GE, Wijermans PW, Wittebol S, Lokhorst HM. Segeren CM, et al. Among authors: van marwijk kooy m, van oers mh, van der holt b. Br J Haematol. 1999 Apr;105(1):127-30. Br J Haematol. 1999. PMID: 10233375 Free article. Clinical Trial.
Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy.
Krol AD, Berenschot HW, Doekharan D, Henzen-Logmans S, van der Holt B, van 't Veer MB. Krol AD, et al. Among authors: van t veer mb, van der holt b. Radiother Oncol. 2001 Mar;58(3):251-5. doi: 10.1016/s0167-8140(00)00272-3. Radiother Oncol. 2001. PMID: 11230885
Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients.
Béné MC, Bernier M, Casasnovas RO, Castoldi G, Doekharan D, van der Holt B, Knapp W, Lemez P, Ludwig WD, Matutes E, Orfao A, Schoch C, Sperling C, van't Veer MB. Béné MC, et al. Among authors: van t veer mb, van der holt b. Br J Haematol. 2001 Jun;113(3):737-45. doi: 10.1046/j.1365-2141.2001.02801.x. Br J Haematol. 2001. PMID: 11380465 Free article. Review.
Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation.
van Esser JW, Niesters HG, Thijsen SF, Meijer E, Osterhaus AD, Wolthers KC, Boucher CA, Gratama JW, Budel LM, van der Holt B, van Loon AM, Löwenberg B, Verdonck LF, Cornelissen JJ. van Esser JW, et al. Among authors: van loon am, van der holt b. Br J Haematol. 2001 Jun;113(3):814-21. doi: 10.1046/j.1365-2141.2001.02789.x. Br J Haematol. 2001. PMID: 11380475 Free article.
Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.
van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF, van Loon AM, Frassoni F, Bacigalupo A, Schaefer UW, Osterhaus AD, Gratama JW, Löwenberg B, Verdonck LF, Cornelissen JJ. van Esser JW, et al. Among authors: van loon am, van der holt b. Blood. 2001 Aug 15;98(4):972-8. doi: 10.1182/blood.v98.4.972. Blood. 2001. PMID: 11493441 Free article.
Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.
van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, Verdonck LF, Löwenberg B, Cornelissen JJ. van Esser JW, et al. Among authors: van der holt b. Blood. 2002 Jun 15;99(12):4364-9. doi: 10.1182/blood.v99.12.4364. Blood. 2002. PMID: 12036863 Free article. Clinical Trial.
195 results